Journal of Breast Cancer最新文献

{"title":"Multidisciplinary Team Intervention: Catalysts for Changing Prognosis in Advanced Breast Cancer.","authors":"Jun-Sheng Zheng, Hui Fu, Zhao Bi, Zhi-Qiang Shi, Jinming Yu, Peng-Fei Qiu, Yong-Sheng Wang","doi":"10.4048/jbc.2025.0001","DOIUrl":"https://doi.org/10.4048/jbc.2025.0001","url":null,"abstract":"<p><strong>Purpose: </strong>Multidisciplinary team (MDT) discussions are standard in cancer care; however, their effect on advanced breast cancer (ABC) prognosis is not well-documented. This study examined the impact of MDT intervention on ABC patient survival.</p><p><strong>Methods: </strong>A retrospective analysis of ABC patients diagnosed 2018 to 2021 was conducted by dividing them into MDT and non-MDT groups. Kaplan-Meier analysis was used to compare progression-free survival (PFS) and overall survival (OS) between the groups. Prognostic factors were evaluated using multivariate Cox regression analysis with subgroup analysis and 1:1 propensity score matching (PSM) to control for confounders.</p><p><strong>Results: </strong>Total 707 patients were included, with 72.8% (515/707) underwent MDT intervention. After a median follow-up of 43.73 months (interquartile range, 34.87-55.67 months), MDT intervention improved the median PFS (12.00 vs. 8.00 months; hazard ratio [HR], 0.75 [95% confidence interval {CI}, 0.63-0.89]; <i>p</i> = 0.001) and median OS (55.67 vs. 40.07 months; HR, 0.77 [95% CI, 0.61-0.97]; <i>p</i> = 0.030). Multivariate Cox analysis showed MDT as an independent factor for disease progression control (HR, 0.82 [95% CI, 0.68-0.98]; <i>p</i> = 0.041), but not for OS (HR, 0.88 [95% CI, 0.69-1.12]; <i>p</i> = 0.286). Subgroup analysis indicated that MDT benefited patients aged ≤ 39 years, those with disease status (<i>de novo</i> metastatic breast cancer), post-menopausal status, T4 stage, N3 stage, G3, visceral metastasis, > one organ metastasis and first-line systemic treatment, regardless of PFS or OS. After PSM, 172 matched patients were in the cohort. MDT still significantly controlled disease progression (12.00 vs. 8.00; HR, 0.74 [95% CI, 0.59-0.93]; <i>p</i> = 0.009) but did not significantly impact the OS (49.00 vs. 39.00; HR, 0.80 [95% CI, 0.59-1.08]; <i>p</i> = 0.121).</p><p><strong>Conclusion: </strong>MDT effectively controlled the disease progression and improved OS in specific patient subgroups.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Nomogram Incorporating Intermuscular Adipose Tissue to Predict Chemotherapy Toxicity in Older Adults With Early-Stage Breast Cancer.","authors":"Wen-Juan Huang, Han-Bing Xie, Lin Zhao, Rui-Han Zhou, Shurui Wang, Xin Zhang, Rui-Tao Wang, Zexun Duan","doi":"10.4048/jbc.2024.0194","DOIUrl":"https://doi.org/10.4048/jbc.2024.0194","url":null,"abstract":"<p><strong>Purpose: </strong>Recent studies have shown that intermuscular adipose tissue (IMAT) is a significant prognostic factor for breast cancer. To date, no clinical studies have investigated whether IMAT can be used to predict chemotherapy toxicity in older adult patients with early-stage breast cancer.</p><p><strong>Methods: </strong>We included 304 patients diagnosed with stage I-III breast cancer between January 2020 and December 2022 in Harbin Medical University Cancer Hospital. All patients were aged ≥ 65 years and treated with neoadjuvant or adjuvant chemotherapy. IMAT within the pectoralis muscle was measured using computed tomography imaging. Logistic regression analysis was used to identify independent predictors of chemotherapy toxicity. A nomogram was built, and the model performance was assessed using accuracy, discrimination, and clinical benefits. The net reclassification index (NRI) and integrated discrimination improvement (IDI) were used to evaluate changes in model performance after the addition of adipose tissue.</p><p><strong>Results: </strong>Of the 304 patients (184 in the training cohort and 120 in the validation cohort), 30.3% developed grade 3-5 chemotherapy toxicities. Three independent predictors were identified in the multivariate analysis: hemoglobin level, IMAT area, and primary prophylaxis with granulocyte colony-stimulating factor. The nomogram demonstrated area under the receiver operating characteristic curve values of 0.708 (95% confidence interval [CI], 0.616-0.801) and 0.751 (95% CI, 0.655-0.846) in the training and validation cohorts, respectively. The nomogram showed good calibration (Hosmer-Lemeshow test, <i>p</i> > 0.05), and incorporating IMAT improved nomogram performance in both cohorts (all NRI and IDI > 0, <i>p</i> < 0.05). Decision curve analysis revealed that the nomogram was clinically useful.</p><p><strong>Conclusion: </strong>A nomogram including IMAT may be useful for predicting the individual probability of chemotherapy toxicity and guiding therapy in older adults with early-stage breast cancer.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus Statement on Robotic Nipple Sparing Mastectomy Expert Panel.","authors":"Jai Min Ryu, Chi Wei Mok, Antonio Toesca, Hung-Wen Lai, Wen-Ling Kuo, Fiona Tsui-Fen Cheng, Seung Yong Song, Jeffrey Johnson, Hyukjai Shin, Hyung Seok Park","doi":"10.4048/jbc.2025.0030","DOIUrl":"https://doi.org/10.4048/jbc.2025.0030","url":null,"abstract":"<p><strong>Purpose: </strong>Since the last consensus statement on robotic nipple-sparing mastectomy (RNSM) in 2019, this technique has gained popularity, with accumulating evidence supporting its feasibility and patient satisfaction. However, concerns regarding the technical challenges and patient selection persist. This study aimed to provide an updated consensus on RNSM.</p><p><strong>Methods: </strong>An international panel of 10 expert surgeons was convened to develop a consensus covering six domains: indications, contraindications, technical considerations, patient counseling, outcome measures, and training. The panel was asked to vote on statements via two rounds of online surveys and a final in-person meeting at the Global Breast Cancer Conference in conjunction with the International Endoscopic and Robotic Breast Surgery Symposium. Consensus was defined as 80% agreement with each statement.</p><p><strong>Results: </strong>A total of 53 statements with at least 80% agreement were generated after three rounds of voting. Most statements were updated from previous consensus statement. All experts agreed that the consensus statement serves as a set of expert recommendations for the successful and safe practice of robotic mastectomy but are not mandatory actions.</p><p><strong>Conclusion: </strong>Although still evolving, RNSM is a promising technique representing the future of minimally invasive breast surgery. This international consensus statement offers expert recommendations for safe and effective RNSM practices.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: \"Targeted Inhibition of p21 Promotes the Growth of Breast Cancer Cells and Impairs the Tumor-Killing Effect of the Vaccinia Virus\".","authors":"Dong-Mei Liu, Meng-Hui Li, Jian Zhang","doi":"10.4048/jbc.2025.0061","DOIUrl":"https://doi.org/10.4048/jbc.2025.0061","url":null,"abstract":"","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and Perspectives in Oncoplastic Breast Surgery: Findings From a Web-Based Survey With the Korean Breast Cancer Society.","authors":"Jeeyeon Lee, Byeongju Kang, Ho Yong Park, Sang Yull Kang, Min Kyoon Kim, Hong-Kyu Kim, Sun Young Min, Min-Ki Seong, Tae-Kyung Robyn Yoo, Seokwon Lee, Eun-Shin Lee, Kyung-Hwak Yoon, Eun-Kyu Kim","doi":"10.4048/jbc.2024.0285","DOIUrl":"https://doi.org/10.4048/jbc.2024.0285","url":null,"abstract":"<p><strong>Purpose: </strong>Oncoplastic breast surgery (OPS) is a crucial component of breast cancer surgery that combines oncological safety with improved cosmetic outcomes. OPS is increasingly being adopted worldwide, although the techniques and concepts vary based on patient demographics and surgeons' expertise. This study aimed to evaluate the evolving OPS concept among Korean breast surgeons and assess the current trends in OPS techniques.</p><p><strong>Methods: </strong>A web-based survey was conducted among members of the Korean Breast Cancer Society and Korean Oncoplastic Breast Surgery Study Group. The questionnaire included seven questions that explored opinions on the scope and practical trends of OPS. Respondents were stratified according to hospital type, position, and age. Data were analyzed to identify trends and differences based on demographic factors.</p><p><strong>Results: </strong>A total of 122 surgeons responded, with a majority (78.7%) working in academic or tertiary hospitals. Most respondents (77.9%) considered OPS to include volume displacement/replacement and implant-based reconstruction, regardless of the resection volume. In addition, 70.5% agreed that robotic or endoscopic surgery fell within the scope of the OPS. Autologous reconstruction after a partial mastectomy is preferred for achieving excellent cosmetic results, particularly among younger surgeons. Notably, 59.0% of the surgeons reported using single- and dual-surgeon strategies.</p><p><strong>Conclusion: </strong>OPS is widely practiced among Korean breast surgeons, with the increasing adoption of advanced techniques such as robotic-assisted and endoscopic surgery. Although preferences differ with the surgeon's age, the concept of OPS has expanded considerably, and a multidisciplinary approach remains critical. Understanding these trends is essential to optimize patient care and improve surgical training programs.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advances in Malignant Phyllodes Tumors of the Breast.","authors":"Eun-Shin Lee","doi":"10.4048/jbc.2024.0284","DOIUrl":"https://doi.org/10.4048/jbc.2024.0284","url":null,"abstract":"<p><p>Phyllodes tumors (PTs) represent an uncommon category of fibroepithelial neoplasms found in the breast tissue and are classified as benign, borderline, or malignant based on their histopathological features. Histological assessment remains the cornerstone of a PT diagnosis. However, recent genomic advancements have revealed the biological mechanisms underlying PTs, particularly malignant phyllodes tumors (MPTs). This comprehensive review integrates current genomic and molecular investigations that have elucidated the distinguishing features of PTs. Mutations in the <i>MED12</i> gene represent early tumorigenic phenomena that are often observed in benign lesions, whereas modifications in the <i>TERT</i> promoter, alterations in <i>TP53</i>, and amplification of <i>EGFR</i> are associated with malignant transformation. Moreover, novel transcriptomic investigations have characterized discrete molecular subtypes exhibiting epithelial and fibrous attributes, thereby enriching our understanding of MPT heterogeneity. Actionable genomic modifications, including dysregulation of the PI3K/Akt/mTOR, MET, and IGF1R signaling cascades, represent promising directions for targeted therapeutic strategies; however, clinical validation is still insufficient. Advances in patient-derived models have created functional platforms conducive to drug screening and preclinical evaluation. Molecular examination has expanded our understanding of PTs, revealing the genomic components linked to malignant progression and identifying prospective therapeutic targets. Nevertheless, obstacles remain in the practical application of these discoveries, primarily owing to the intratumoral heterogeneity and rarity of MPTs. Future investigations should prioritize the integration of diverse omics methodologies, enhancement of preclinical testing frameworks, and establishment of global data-sharing initiatives to promote biomarker-driven treatment strategies.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"28 2","pages":"51-60"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DNA Methyltransferases 1-Regulated Methylation of Protein Kinase C Zeta Influences Its Expression in Breast Cancer Cells.","authors":"Xixun Zhang, Lianglan Bao, Mengya Sun, Jinbin Chen","doi":"10.4048/jbc.2024.0201","DOIUrl":"10.4048/jbc.2024.0201","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer (BC) is a predominant malignancy globally, surpassing lung cancer in terms of diagnostic frequency, with an escalating incidence rate in recent decades. Recent studies have investigated the role of protein kinase C zeta (PRKCZ) in diverse cellular processes in cancer biology. In this study, we evaluated the association between PRKCZ and deleterious outcomes in BC and elucidated the mechanisms underlying its expression in breast carcinoma.</p><p><strong>Methods: </strong>The correlation between PRKCZ and survival rates of patients with BC was investigated using The Cancer Genome Atlas database. The methylation status of the PRKCZ promoter was analyzed using the UALCAN database. Furthermore, we investigated the mechanisms underlying PRKCZ inactivation in BC by treatment with transferase inhibitors, methylation-specific polymerase chain reaction (PCR) analysis, western blotting, and luciferase reporter gene assays. The degree of methylation and expression levels of PRKCZ, as regulated by DNA methyltransferase 1 (DNMT1), were quantified using quantitative PCR and western blotting.</p><p><strong>Results: </strong>Our analysis revealed that decreased expression of PRKCZ in BC was significantly correlated with poor clinical prognosis. Furthermore, we observed that hypermethylation of the PRKCZ promoter contributed to its reduced expression in BC. Notably, DNMT1 has been identified as a critical regulator of PRKCZ methylation.</p><p><strong>Conclusion: </strong>Our findings elucidate the tumor-suppressive function of PRKCZ and provide insights into the molecular mechanisms underlying its downregulation in BC.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"72-85"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Intercostal Nerve Coaptation on Postoperative Pain in Implant-Based Breast Reconstruction: A Double-Blind, Randomized Controlled Pilot Study.","authors":"Ji-Young Kim, Jeong Hyun Ha, Ung Sik Jin","doi":"10.4048/jbc.2024.0212","DOIUrl":"10.4048/jbc.2024.0212","url":null,"abstract":"<p><strong>Purpose: </strong>Patients undergoing breast surgery may experience chronic postoperative pain in the breasts, upper extremities, and axillary regions, and no established methods for preventing this pain are available at present. This study aimed to investigate whether coaptation of the transected intercostal nerve can prevent the development of neuropathic and chronic breast pain after mastectomy in implant-based breast reconstruction.</p><p><strong>Methods: </strong>A prospective, double-blind, randomized controlled trial was conducted by dividing patients who underwent implant-based breast reconstruction after mastectomy into a control group without nerve coaptation and an experimental group with nerve coaptation. Patient clinical information was collected, and a survey using the pain and quality of life scale was conducted at 6 and 12 months after surgery.</p><p><strong>Results: </strong>Fifteen patients completed the study, including seven in the control group and eight in the experimental group. The two groups showed no significant differences in terms of clinical factors. The experimental group exhibited lower Short-Form McGill Pain Questionnaire scores than the control group at 6 and 12 months postoperatively, with a statistically significant difference at 6 months. Numerical Rating Scale and Present Pain Intensity scores for both groups were in the \"no to mild\" range throughout the study period, with no statistically significant differences between the groups. Although the difference in the BREAST-Q™ results did not reach statistical significance, the experimental group showed an improvement in the quality of life.</p><p><strong>Conclusion: </strong>Intercostal nerve coaptation after mastectomy in implant-based breast reconstruction may facilitate initial nerve recovery. Although trial results are needed to fully determine the clinical impact, our findings support the ongoing scientific and clinical efforts to use this technique.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"108-118"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiological Considerations in Diagnosing Angiosarcoma Associated With Lymphedema Following Breast Cancer Surgery.","authors":"Eun Jung Choi, Gwang Min Chae, Jinyong Shin, Si-Gyun Roh, Nae-Ho Lee","doi":"10.4048/jbc.2024.0297","DOIUrl":"https://doi.org/10.4048/jbc.2024.0297","url":null,"abstract":"<p><p>Angiosarcoma associated with lymphedema is a rare soft tissue malignancy that occurs owing to chronic lymphedema, primarily following breast cancer surgery. We present a case of an 83-year-old female who developed angiosarcoma 14 years after undergoing breast cancer surgery. Diagnosis was confirmed through excisional biopsy, histopathological evaluation, and imaging. Computed tomography and magnetic resonance imaging revealed diffuse dermal thickening with an enhanced subcutaneous nodular lesion on the right arm. This unusual case emphasizes the importance of vigilant monitoring in patients with chronic lymphedema post-breast cancer surgery, as early radiologic and clinical detection can facilitate timely intervention and improve outcomes.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"28 2","pages":"119-124"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer in Older Patients Aged 70 Years and Above: Treatment Adherence and Oncologic Outcomes.","authors":"Ji Hye Kim, Yong Yeup Kim, Jai Hyun Chung, Woo Young Kim, Jae Bok Lee, Sang Uk Woo","doi":"10.4048/jbc.2024.0190","DOIUrl":"10.4048/jbc.2024.0190","url":null,"abstract":"<p><strong>Purpose: </strong>The incidence of breast cancer in older females is increasing with increased life expectancy. This study analyzed tumor characteristics and oncological outcomes in patients aged ≥ 70 years compared to patients in a younger postmenopausal group, in conjunction with their adherence to treatment guidelines.</p><p><strong>Methods: </strong>Patients aged ≥ 50 years, newly diagnosed with breast cancer, were divided into two age categories: ≥ 70 years and 50-69 years. All patients underwent curative surgery at Korea University Guro Hospital between January 2009 and December 2019. Clinical data on tumor subtype, histopathological grade, and clinical stage, along with treatment details were collected. Disease-free survival, distant recurrence-free survival, and breast cancer-specific survival rates were determined.</p><p><strong>Results: </strong>Of 1,199 patients, 166 (13.8%) were ≥ 70 years at the time of surgery. The disease-free, distant recurrence-free, and breast cancer-specific survival rates were significantly lower in patients aged ≥ 70 years (<i>p</i> < 0.05). In a subgroup analysis, human epidermal growth factor receptor 2-positive tumors were the only subtype with a statistically significant difference in survival outcomes, and adherence to the guidelines was strongly linked to a better prognosis.</p><p><strong>Conclusion: </strong>Patients aged ≥ 70 years had lower disease-free, distant recurrence-free, and breast cancer-specific survival rates compared to younger postmenopausal patients aged 50-69 years. With the continuous increase in life expectancy and advances in healthcare, it is critical to optimize treatment strategies for older patients with breast cancer to improve survival outcomes and enhance their quality of life.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"99-107"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}